Dr. Reddy's Laboratories Future Growth

Future criteria checks 1/6

Dr. Reddy's Laboratories is forecast to grow earnings and revenue by 2.5% and 6.5% per annum respectively. EPS is expected to grow by 3% per annum. Return on equity is forecast to be 13.7% in 3 years.

Key information

2.5%

Earnings growth rate

3.0%

EPS growth rate

Pharmaceuticals earnings growth	23.0%
Revenue growth rate	6.5%
Future return on equity	13.7%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

No updates

Recent updates

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Dr. Reddy's in talks to bring single-dose Sputnik Light vaccine in India

May 31

Earnings and Revenue Growth Forecasts

NYSE:RDY - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	339,601	53,132	41,034	56,034	3
3/31/2026	316,757	56,985	48,505	64,337	30
3/31/2025	298,748	56,739	48,242	61,812	32
3/31/2024	278,772	54,644	34,468	52,175	34
12/31/2023	271,302	52,206	28,713	53,592	N/A
9/30/2023	266,854	50,888	49,179	72,115	N/A
6/30/2023	261,109	47,216	41,123	63,470	N/A
3/31/2023	245,879	45,067	40,009	58,875	N/A
12/31/2022	237,279	36,350	29,170	48,315	N/A
9/30/2022	222,776	30,944	21,866	42,386	N/A
6/30/2022	217,351	29,736	16,755	38,211	N/A
3/31/2022	214,391	23,568	12,005	28,108	N/A
12/31/2021	207,307	26,317	14,976	30,255	N/A
9/30/2021	203,406	19,450	1,597	17,194	N/A
6/30/2021	194,741	17,153	7,335	21,342	N/A
3/31/2021	189,722	17,238	23,142	35,703	N/A
12/31/2020	186,756	21,256	15,528	26,983	N/A
9/30/2020	181,298	15,361	22,026	30,069	N/A
6/30/2020	180,340	18,663	24,354	30,921	N/A
3/31/2020	174,600	19,498	23,985	29,841	N/A
12/31/2019	170,448	16,200	28,930	34,006	N/A
9/30/2019	165,110	26,749	37,511	42,937	N/A
6/30/2019	155,079	20,862	37,400	43,559	N/A
3/31/2019	153,851	18,795	21,213	28,704	N/A
12/31/2018	149,034	17,473	19,953	27,774	N/A
9/30/2018	148,594	15,965	9,576	19,007	N/A
6/30/2018	145,903	13,776	4,490	14,986	N/A
3/31/2018	141,855	9,806	6,986	18,029	N/A
12/31/2017	141,827	9,909	8,017	20,765	N/A
9/30/2017	140,588	11,266	N/A	18,478	N/A
6/30/2017	140,907	11,367	N/A	14,480	N/A
3/31/2017	139,870	12,039	N/A	21,513	N/A
12/31/2016	141,269	9,660	N/A	22,252	N/A
9/30/2016	144,127	10,751	N/A	29,018	N/A
6/30/2016	148,410	15,019	N/A	37,693	N/A
3/31/2016	153,866	20,013	N/A	41,247	N/A
12/31/2015	155,850	24,456	N/A	42,252	N/A
9/30/2015	154,602	24,409	N/A	36,012	N/A
6/30/2015	150,592	22,932	N/A	29,083	N/A
3/31/2015	147,360	22,179	N/A	25,033	N/A
12/31/2014	143,474	21,806	N/A	22,860	N/A
9/30/2014	140,380	22,247	N/A	23,151	N/A
6/30/2014	138,076	23,409	N/A	19,532	N/A
3/31/2014	132,170	21,515	N/A	19,463	N/A
12/31/2013	130,043	22,409	N/A	13,951	N/A
9/30/2013	123,357	20,005	N/A	11,428	N/A
6/30/2013	118,591	17,027	N/A	13,919	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDY's forecast earnings growth (2.5% per year) is above the savings rate (2.3%).

Earnings vs Market: RDY's earnings (2.5% per year) are forecast to grow slower than the US market (14.8% per year).

High Growth Earnings: RDY's earnings are forecast to grow, but not significantly.

Revenue vs Market: RDY's revenue (6.5% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: RDY's revenue (6.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RDY's Return on Equity is forecast to be low in 3 years time (13.7%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dr. Reddy's Laboratories Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's launches generic drugs for allergies in US

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2022

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jun 29, 2022

Dr. Reddy's Laboratories Limited Launches Posaconazole Delayed-Release Tablets in the U.S. Market

Torrent, JB Chemicals Reportedly in Final Race to Acquire Curatio Healthcare

Dr. Reddy's Laboratories Limited Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr. Reddy's Laboratories Limited to Report Q4, 2022 Results on May 19, 2022

Dr Reddy's, Biocon Reportedly Among 6 Drug Companies in Race for Curatio

Alium JSC entered into agreement to acquire Two anti-bacterial brand Ciprolet and Levolet from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT Vials in the U.S. Market

Dr. Reddy's Laboratories Limited Announces DCGI Approval to the Single-Shot Sputnik Light Vaccine in India

Dr. Reddy's Laboratories Limited (BSE:500124) agreed to acquire Nimbus Health GmbH.

Dr. Reddy's Laboratories Limited Appoints Penny Wan as an Additional Director

Dr. Reddy's Laboratories Limited Receives DCGI Approval to Launch Molnupiravir Capsules 200Mg (Molflu™) in India

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

Dr. Reddy's Launches Hair Loss Treatment Drug for Women

Citius Pharmaceuticals, Inc. (NasdaqCM:CTXR) agreed to acquire Rights and Certain Related Assets of Dr. Reddy's Laboratories Limited (BSE:500124) for approximately $150 million.